175 related articles for article (PubMed ID: 37958457)
1. Discovery, Structure-Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein-Protein Interactions between AF9/ENL and AF4 or DOT1L.
Li X; Wu X; Nie S; Zhao J; Yao Y; Wu F; Mishra CB; Ashraf-Uz-Zaman M; Moku BK; Song Y
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958457
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
3. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
[TBL] [Abstract][Full Text] [Related]
5. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
6. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
7. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
[TBL] [Abstract][Full Text] [Related]
8. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
9. Peptidomimetics for Targeting Protein-Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL.
Du L; Grigsby SM; Yao A; Chang Y; Johnson G; Sun H; Nikolovska-Coleska Z
ACS Med Chem Lett; 2018 Sep; 9(9):895-900. PubMed ID: 30258537
[TBL] [Abstract][Full Text] [Related]
10. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract][Full Text] [Related]
11. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth.
Li X; Yao Y; Wu F; Song Y
J Hematol Oncol; 2022 Apr; 15(1):41. PubMed ID: 35395864
[TBL] [Abstract][Full Text] [Related]
12. Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.
Watson VG; Drake KM; Peng Y; Napper AD
Assay Drug Dev Technol; 2013 May; 11(4):253-68. PubMed ID: 23679849
[TBL] [Abstract][Full Text] [Related]
13. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
14. BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity.
Schmidt CR; Achille NJ; Kuntimaddi A; Boulton AM; Leach BI; Zhang S; Zeleznik-Le NJ; Bushweller JH
Blood Cancer Discov; 2020 Sep; 1(2):162-177. PubMed ID: 32954361
[TBL] [Abstract][Full Text] [Related]
15. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins.
Li X; Song Y
J Hematol Oncol; 2021 Apr; 14(1):56. PubMed ID: 33823889
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis.
Grigsby SM; Friedman A; Chase J; Waas B; Ropa J; Serio J; Shen C; Muntean AG; Maillard I; Nikolovska-Coleska Z
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562706
[No Abstract] [Full Text] [Related]
17. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
18. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
20. The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
Hu H; Muntean AG
Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
